PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15255281-5 2004 Treatment with IL-1alpha (10 ng/ml) significantly augmented (4- to 60-fold) the secretion of PGI2, prostaglandin E2 (PGE2), prostaglandin F2alpha (PGF2alpha) and thromboxane A2 (TXA2) from cultured human myometrial cells obtained from non-pregnant and pregnant women as well as in cultured human umbilical artery and cultured human coronary artery smooth muscle cells (p < 0.05 for all comparisons). Epoprostenol 93-97 interleukin 1 alpha Homo sapiens 15-24 15255281-0 2004 Cyclic mechanical stretching and interleukin-1alpha synergistically up-regulate prostacyclin secretion in cultured human uterine myometrial cells. Epoprostenol 80-92 interleukin 1 alpha Homo sapiens 33-51 15255281-6 2004 However, labor-like cyclic mechanical stretching up-regulated IL-1alpha-augmented PGI2 secretion from myometrial cells obtained from non-pregnant and pregnant women 2.1- to 2.8-fold (p < 0.05 for all comparisons), but not PGE2, PGF2alpha nor TXA2. Epoprostenol 82-86 interleukin 1 alpha Homo sapiens 62-71 15255281-8 2004 These results suggest that cyclic mechanical stretching by labor, in concert with IL-1alpha stimulation, contributes to the increase in myometrial PGI2 secretion during delivery. Epoprostenol 147-151 interleukin 1 alpha Homo sapiens 82-91 12068797-3 2002 The presence of interleukin-1 in the perfusion system, as a model for inflammatory cytokine effects, enhanced the overall amounts of released prostacyclin but did not affect the production of endothelin-1. Epoprostenol 142-154 interleukin 1 alpha Homo sapiens 16-29 10454832-11 1999 Conversely, IL-1 helps to maintain stroke volume and low SVRI in graded bacteremia, possibly through increased prostacyclin release. Epoprostenol 111-123 interleukin 1 alpha Homo sapiens 12-16 11546664-7 2001 These results show that IL-1 alpha causes an acute upregulation of PGI(2) generation in HUVEC, establish a role for the MEK/ERK/cPLA(2)alpha pathway in this early release, and provide evidence for an agonist-specific cross talk between p38(mapk) and p42/44(mapk) that may reflect receptor-specific differences in the signaling elements proximal to MAPK activation. Epoprostenol 67-73 interleukin 1 alpha Homo sapiens 24-34 11360675-0 2000 Effects of antisense IRAK-2 oligonucleotides on PGI2 release induced by IL-1 and TNF. Epoprostenol 48-52 interleukin 1 alpha Homo sapiens 72-76 11360675-1 2000 AIM: To explore the effects of antisense interleukin-1 receptor associated kinase-2 oligonucleotide (IRAK-2 ODN) on the prostacyclin (PGI2) synthesis in human umbilical vein endothelial cells (HUVEC) induced by interleukin-1 (IL-1) and tumor necrosis factor (TNF). Epoprostenol 120-132 interleukin 1 alpha Homo sapiens 41-54 11360675-1 2000 AIM: To explore the effects of antisense interleukin-1 receptor associated kinase-2 oligonucleotide (IRAK-2 ODN) on the prostacyclin (PGI2) synthesis in human umbilical vein endothelial cells (HUVEC) induced by interleukin-1 (IL-1) and tumor necrosis factor (TNF). Epoprostenol 134-138 interleukin 1 alpha Homo sapiens 41-54 11360675-4 2000 RESULTS: Pre-transfection with antisense IRAK-2 ODN could remarkably decrease the levels of PGI2 synthesis induced by IL-1 in a time- and concentration-dependent manner, whereas it could not attenuate the one stimulated by TNF. Epoprostenol 92-96 interleukin 1 alpha Homo sapiens 118-122 11360675-6 2000 IRAK-2 plays a key role in the IL-1 signaling events leading to PGI2 release. Epoprostenol 64-68 interleukin 1 alpha Homo sapiens 31-35 10367586-7 1999 These results suggest the existence of regulatory mechanisms of IL-1alpha-induced PGI2 production, which involve PGHS and PLA2 gene transcription. Epoprostenol 82-86 interleukin 1 alpha Homo sapiens 64-73 11546664-1 2001 We have examined the mechanisms regulating prostacyclin (PGI(2)) synthesis after acute exposure of human umbilical vein endothelial cells (HUVEC) to interleukin-1 alpha (IL-1 alpha). Epoprostenol 43-55 interleukin 1 alpha Homo sapiens 149-168 11546664-1 2001 We have examined the mechanisms regulating prostacyclin (PGI(2)) synthesis after acute exposure of human umbilical vein endothelial cells (HUVEC) to interleukin-1 alpha (IL-1 alpha). Epoprostenol 43-55 interleukin 1 alpha Homo sapiens 170-180 11546664-1 2001 We have examined the mechanisms regulating prostacyclin (PGI(2)) synthesis after acute exposure of human umbilical vein endothelial cells (HUVEC) to interleukin-1 alpha (IL-1 alpha). Epoprostenol 57-63 interleukin 1 alpha Homo sapiens 149-168 11546664-4 2001 The mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors, PD-98059 and U-0126, blocked IL-1 alpha-induced ERK activation and partially attenuated cPLA(2)alpha phosphorylation and PGI(2) release, suggesting that ERK-dependent and -independent pathways regulate cPLA(2)alpha phosphorylation. Epoprostenol 190-196 interleukin 1 alpha Homo sapiens 98-108 10367586-0 1999 Interleukin-1alpha stimulated prostacyclin release by increasing gene transcription of prostaglandin H synthase and phospholipase A2 in human vascular endothelial cells. Epoprostenol 30-42 interleukin 1 alpha Homo sapiens 0-18 10367586-1 1999 This study was conducted to evaluate the effects of interleukin-1alpha (IL-1alpha) on prostacyclin (PGI2) production in cultured human vascular endothelial cells in association with intracellular Ca2+, inositol 1,4,5-trisphosphate (IP3), and with prostaglandin H synthase (PGHS) and phospholipase A2 (PLA2) gene expression by using the competitive polymerase chain reaction (PCR) method. Epoprostenol 86-98 interleukin 1 alpha Homo sapiens 52-70 10367586-1 1999 This study was conducted to evaluate the effects of interleukin-1alpha (IL-1alpha) on prostacyclin (PGI2) production in cultured human vascular endothelial cells in association with intracellular Ca2+, inositol 1,4,5-trisphosphate (IP3), and with prostaglandin H synthase (PGHS) and phospholipase A2 (PLA2) gene expression by using the competitive polymerase chain reaction (PCR) method. Epoprostenol 86-98 interleukin 1 alpha Homo sapiens 72-81 10367586-1 1999 This study was conducted to evaluate the effects of interleukin-1alpha (IL-1alpha) on prostacyclin (PGI2) production in cultured human vascular endothelial cells in association with intracellular Ca2+, inositol 1,4,5-trisphosphate (IP3), and with prostaglandin H synthase (PGHS) and phospholipase A2 (PLA2) gene expression by using the competitive polymerase chain reaction (PCR) method. Epoprostenol 100-104 interleukin 1 alpha Homo sapiens 52-70 10367586-1 1999 This study was conducted to evaluate the effects of interleukin-1alpha (IL-1alpha) on prostacyclin (PGI2) production in cultured human vascular endothelial cells in association with intracellular Ca2+, inositol 1,4,5-trisphosphate (IP3), and with prostaglandin H synthase (PGHS) and phospholipase A2 (PLA2) gene expression by using the competitive polymerase chain reaction (PCR) method. Epoprostenol 100-104 interleukin 1 alpha Homo sapiens 72-81 10454832-14 1999 IL-1 is required for increased leukotriene and prostacyclin levels in this model, but it is not involved in thromboxane release. Epoprostenol 47-59 interleukin 1 alpha Homo sapiens 0-4 10209072-4 1999 IL-1alpha (100 U/ml) increased prostacyclin (PGI2) (measured as 6-keto PGF1alpha[6K]) synthesis in endothelial cells and the production of PGE2in fibroblasts. Epoprostenol 31-43 interleukin 1 alpha Homo sapiens 0-9 10209072-4 1999 IL-1alpha (100 U/ml) increased prostacyclin (PGI2) (measured as 6-keto PGF1alpha[6K]) synthesis in endothelial cells and the production of PGE2in fibroblasts. Epoprostenol 45-49 interleukin 1 alpha Homo sapiens 0-9 10209072-7 1999 IL- 1beta (100 U/ml) was as active as IL-1alpha in triggering release of PGI2 from endothelial cells and PGE2 from fibroblasts. Epoprostenol 73-77 interleukin 1 alpha Homo sapiens 38-47 7649115-3 1995 Recombinant human interleukin-1 alpha (IL-1 alpha) increased prostacyclin synthesis in endothelial cells by 66% and prostaglandin E2 (PGE2) synthesis in fibroblasts by 91%. Epoprostenol 61-73 interleukin 1 alpha Homo sapiens 18-37 9561191-0 1997 Stimulation of PG I2-synthesis in the periodontal tissue by interleukin-1 alpha and -1 beta. Epoprostenol 15-20 interleukin 1 alpha Homo sapiens 60-91 8796788-1 1996 The objective of this study was to characterize interleukin-1, -6, and -8 (IL-1-, IL-6-, and IL-8)-induced prostacyclin (PGI2 as 6-keto PGF1 alpha) and prostaglandin E2 (PGE2) production in primary cultures of human myometrial cells. Epoprostenol 107-119 interleukin 1 alpha Homo sapiens 48-73 8796788-1 1996 The objective of this study was to characterize interleukin-1, -6, and -8 (IL-1-, IL-6-, and IL-8)-induced prostacyclin (PGI2 as 6-keto PGF1 alpha) and prostaglandin E2 (PGE2) production in primary cultures of human myometrial cells. Epoprostenol 107-119 interleukin 1 alpha Homo sapiens 75-79 8796788-1 1996 The objective of this study was to characterize interleukin-1, -6, and -8 (IL-1-, IL-6-, and IL-8)-induced prostacyclin (PGI2 as 6-keto PGF1 alpha) and prostaglandin E2 (PGE2) production in primary cultures of human myometrial cells. Epoprostenol 121-125 interleukin 1 alpha Homo sapiens 48-73 8796788-1 1996 The objective of this study was to characterize interleukin-1, -6, and -8 (IL-1-, IL-6-, and IL-8)-induced prostacyclin (PGI2 as 6-keto PGF1 alpha) and prostaglandin E2 (PGE2) production in primary cultures of human myometrial cells. Epoprostenol 121-125 interleukin 1 alpha Homo sapiens 75-79 8796788-3 1996 IL-1, but not IL-6 or IL-8, caused a dose- and time-dependent increase in the production of both PGI2 and PGE2. Epoprostenol 97-101 interleukin 1 alpha Homo sapiens 0-4 7649115-3 1995 Recombinant human interleukin-1 alpha (IL-1 alpha) increased prostacyclin synthesis in endothelial cells by 66% and prostaglandin E2 (PGE2) synthesis in fibroblasts by 91%. Epoprostenol 61-73 interleukin 1 alpha Homo sapiens 39-49 7578979-0 1995 Interleukin 1 induces prostacyclin-dependent increases in cyclic AMP production and does not affect cyclic GMP production in human vascular smooth muscle cells. Epoprostenol 22-34 interleukin 1 alpha Homo sapiens 0-13 7578979-3 1995 IL-1-induced cAMP was associated with a marked increase in prostacyclin (PGI2) production, and was reversed by indomethacin and tranylcypromine, inhibitors of cyclooxygenase and PGI2 synthetase respectively. Epoprostenol 59-71 interleukin 1 alpha Homo sapiens 0-4 7578979-3 1995 IL-1-induced cAMP was associated with a marked increase in prostacyclin (PGI2) production, and was reversed by indomethacin and tranylcypromine, inhibitors of cyclooxygenase and PGI2 synthetase respectively. Epoprostenol 73-77 interleukin 1 alpha Homo sapiens 0-4 7578979-4 1995 Furthermore, PGI2, but not PGE2, was a potent inducer of cAMP production in HSVSMC, implicating a role for PGI2 in mediating IL-1-induced cAMP production. Epoprostenol 13-17 interleukin 1 alpha Homo sapiens 125-129 7578979-4 1995 Furthermore, PGI2, but not PGE2, was a potent inducer of cAMP production in HSVSMC, implicating a role for PGI2 in mediating IL-1-induced cAMP production. Epoprostenol 107-111 interleukin 1 alpha Homo sapiens 125-129 7578979-7 1995 The results implicate prostacyclin-dependent cAMP production as a mediator of the vasodilatory effects of IL-1 in humans. Epoprostenol 22-34 interleukin 1 alpha Homo sapiens 106-110 7641804-6 1995 Under the first condition, basal PGI2 production was unaffected while, in the presence of IL-1 alpha, a marked stimulation of PGI2 synthesis was observed. Epoprostenol 126-130 interleukin 1 alpha Homo sapiens 90-100 7641804-8 1995 Two lines of evidence indicate that PGI2 synthase is a constitutively expressed not inducible enzyme: (a) proliferating nonproducing cells when added with PGH2 produce an amount of PGI2 not different from the amount produced by cells stimulated with IL-1 alpha; (b) under this condition PGI2 synthase was immunodetectable either by immunofluorescence detected by confocal microscopy or by ELISA and, on microsomes isolated from endothelial cells, by Western blotting. Epoprostenol 36-40 interleukin 1 alpha Homo sapiens 250-260 8020193-6 1994 With respect to EC prostacyclin production, although retinoic acid alone had no effect, cis and trans-retinoic acid and retinol all induced a dose-dependent increase in IL-1-mediated prostacyclin production, which was most marked at higher concentrations (20 U/ml) of IL-1. Epoprostenol 19-31 interleukin 1 alpha Homo sapiens 169-173 8020193-6 1994 With respect to EC prostacyclin production, although retinoic acid alone had no effect, cis and trans-retinoic acid and retinol all induced a dose-dependent increase in IL-1-mediated prostacyclin production, which was most marked at higher concentrations (20 U/ml) of IL-1. Epoprostenol 183-195 interleukin 1 alpha Homo sapiens 169-173 8020193-6 1994 With respect to EC prostacyclin production, although retinoic acid alone had no effect, cis and trans-retinoic acid and retinol all induced a dose-dependent increase in IL-1-mediated prostacyclin production, which was most marked at higher concentrations (20 U/ml) of IL-1. Epoprostenol 183-195 interleukin 1 alpha Homo sapiens 268-272 8321913-0 1993 Augmentation of interleukin-1 induced prostacyclin production by endothelial cell growth factor: implications for chronic synovitis. Epoprostenol 38-50 interleukin 1 alpha Homo sapiens 16-29 8248272-2 1993 HUVEC which had been preincubated with LPS, interleukin-1 alpha (IL-1 alpha), IL-1 beta, tumor necrosis factor (TNF alpha), or interferon-gamma (IFN-gamma) produced more PGI2 than control cells in response to thrombin. Epoprostenol 170-174 interleukin 1 alpha Homo sapiens 44-63 8248272-2 1993 HUVEC which had been preincubated with LPS, interleukin-1 alpha (IL-1 alpha), IL-1 beta, tumor necrosis factor (TNF alpha), or interferon-gamma (IFN-gamma) produced more PGI2 than control cells in response to thrombin. Epoprostenol 170-174 interleukin 1 alpha Homo sapiens 65-75 8473346-9 1993 Stimulation of the cells with tumor necrosis factor, phorbol 12-myristate 13-acetate, lipopolysaccharide, or interleukin-1 increased mRNA levels for PHS II, and this change correlated well with increased prostacyclin biosynthesis. Epoprostenol 204-216 interleukin 1 alpha Homo sapiens 109-122 8213348-6 1993 Cytokines IL-1 alpha and TNF were also able to stimulate PGI2 synthesis, although to a lesser extent. Epoprostenol 57-61 interleukin 1 alpha Homo sapiens 10-20 1694171-1 1990 The monokine interleukin-1 (IL-1) inhibits endothelial cell growth and induces prostacyclin production in human endothelial cells. Epoprostenol 79-91 interleukin 1 alpha Homo sapiens 13-26 1333514-12 1992 Furthermore, short (5 minute) pretreatment with phorbol myristate acetate dramatically augmented interleukin 1-mediated prostacyclin responses in synergistic fashion, suggesting that protein kinase C may modulate interleukin 1 signal transducing pathways. Epoprostenol 120-132 interleukin 1 alpha Homo sapiens 97-110 1333514-12 1992 Furthermore, short (5 minute) pretreatment with phorbol myristate acetate dramatically augmented interleukin 1-mediated prostacyclin responses in synergistic fashion, suggesting that protein kinase C may modulate interleukin 1 signal transducing pathways. Epoprostenol 120-132 interleukin 1 alpha Homo sapiens 213-226 2127553-0 1990 Interleukin-1 potentiates histamine-induced release of prostacyclin from human endothelial cells. Epoprostenol 55-67 interleukin 1 alpha Homo sapiens 0-13 2127553-2 1990 In human cultured umbilical vein endothelial cells, interleukin-1 potentiated histamine-induced release of prostacyclin in a time- and concentration-dependent manner. Epoprostenol 107-119 interleukin 1 alpha Homo sapiens 52-65 2127553-6 1990 In cells incubated with 0.5 u ml-1 interleukin-1, 20 min pre-incubation was sufficient to induce a statistically significant potentiation of prostacyclin release induced by 1 microM histamine (P less than 0.05). Epoprostenol 141-153 interleukin 1 alpha Homo sapiens 35-48 2285018-8 1990 The results suggest that IL-1 released in monocyte neutrophil co-cultures can produce prothrombotic (increased PCA expression) and inflammatory changes (increased synthesis of vasodilatory and permeability enhancing PGI2 and PGE2) in endothelial cells. Epoprostenol 216-220 interleukin 1 alpha Homo sapiens 25-29 1333514-0 1992 Interleukin 1-stimulated prostacyclin synthesis in endothelium: lack of phospholipase C, phospholipase D, or protein kinase C involvement in early signal transduction. Epoprostenol 25-37 interleukin 1 alpha Homo sapiens 0-13 1333514-9 1992 The intracellular Ca++ antagonist BAPTA and the extracellular Ca++ chelator EGTA produced significant inhibition of interleukin 1-beta-stimulated prostacyclin generation at 4 to 8 hours, suggesting either an indirect inhibitory effect of these agents on phospholipase A2 activity or that an increase in Ca++ may be a late event in the transduction scheme after interleukin 1 stimulation. Epoprostenol 146-158 interleukin 1 alpha Homo sapiens 116-129 2127553-8 1990 Nifedipine but not cycloheximide, significantly (P less than 0.05) inhibited histamine-induced release of prostacyclin and interleukin-1 potentiation of histamine-induced release of prostacyclin (P less than 0.05). Epoprostenol 182-194 interleukin 1 alpha Homo sapiens 123-136 2127553-14 1990 These results suggest that interleukin-1 potentiates histamine-induced release of prostacyclin by rapid up-regulation of prostaglandin synthetase activity as well as by inducing synthesis of enzyme protein. Epoprostenol 82-94 interleukin 1 alpha Homo sapiens 27-40 1694171-1 1990 The monokine interleukin-1 (IL-1) inhibits endothelial cell growth and induces prostacyclin production in human endothelial cells. Epoprostenol 79-91 interleukin 1 alpha Homo sapiens 28-32 1694171-3 1990 Our data demonstrate that 1) the Cox mRNA is expressed at low levels in untreated cells; 2) IL-1 alpha induces the Cox mRNA within 2 h, and this induction is sustained for more than 24 h; 3) IL-1 alpha induction is dose-dependent; 4) cycloheximide potentiates the induction of the Cox mRNA by IL-1 alpha while actinomycin D prevents the induction, and 5) IL-1 alpha also stimulates Cox production in a time-dependent fashion which correlates with the increase in prostacyclin synthesis. Epoprostenol 463-475 interleukin 1 alpha Homo sapiens 92-102 1694171-3 1990 Our data demonstrate that 1) the Cox mRNA is expressed at low levels in untreated cells; 2) IL-1 alpha induces the Cox mRNA within 2 h, and this induction is sustained for more than 24 h; 3) IL-1 alpha induction is dose-dependent; 4) cycloheximide potentiates the induction of the Cox mRNA by IL-1 alpha while actinomycin D prevents the induction, and 5) IL-1 alpha also stimulates Cox production in a time-dependent fashion which correlates with the increase in prostacyclin synthesis. Epoprostenol 463-475 interleukin 1 alpha Homo sapiens 191-201 1694171-3 1990 Our data demonstrate that 1) the Cox mRNA is expressed at low levels in untreated cells; 2) IL-1 alpha induces the Cox mRNA within 2 h, and this induction is sustained for more than 24 h; 3) IL-1 alpha induction is dose-dependent; 4) cycloheximide potentiates the induction of the Cox mRNA by IL-1 alpha while actinomycin D prevents the induction, and 5) IL-1 alpha also stimulates Cox production in a time-dependent fashion which correlates with the increase in prostacyclin synthesis. Epoprostenol 463-475 interleukin 1 alpha Homo sapiens 191-201 1694171-3 1990 Our data demonstrate that 1) the Cox mRNA is expressed at low levels in untreated cells; 2) IL-1 alpha induces the Cox mRNA within 2 h, and this induction is sustained for more than 24 h; 3) IL-1 alpha induction is dose-dependent; 4) cycloheximide potentiates the induction of the Cox mRNA by IL-1 alpha while actinomycin D prevents the induction, and 5) IL-1 alpha also stimulates Cox production in a time-dependent fashion which correlates with the increase in prostacyclin synthesis. Epoprostenol 463-475 interleukin 1 alpha Homo sapiens 191-201 2497185-6 1989 Enhanced thrombin-stimulated PGI2 production was also observed in HUVEC pretreated with the related cytokines IL-1 alpha, TNF, or lymphotoxin. Epoprostenol 29-33 interleukin 1 alpha Homo sapiens 110-120 2105090-0 1990 Interleukin-1 stimulates prostacyclin production by cultured human endothelial cells by increasing arachidonic acid mobilization and conversion. Epoprostenol 25-37 interleukin 1 alpha Homo sapiens 0-13 2105090-1 1990 Interleukin-1 (IL-1) induced slow, lasting activation of human endothelial cells (EC) to release prostacyclin (PGI2). Epoprostenol 97-109 interleukin 1 alpha Homo sapiens 0-13 2105090-1 1990 Interleukin-1 (IL-1) induced slow, lasting activation of human endothelial cells (EC) to release prostacyclin (PGI2). Epoprostenol 97-109 interleukin 1 alpha Homo sapiens 15-19 2105090-1 1990 Interleukin-1 (IL-1) induced slow, lasting activation of human endothelial cells (EC) to release prostacyclin (PGI2). Epoprostenol 111-115 interleukin 1 alpha Homo sapiens 0-13 2105090-1 1990 Interleukin-1 (IL-1) induced slow, lasting activation of human endothelial cells (EC) to release prostacyclin (PGI2). Epoprostenol 111-115 interleukin 1 alpha Homo sapiens 15-19 2105090-3 1990 The continuous presence of IL-1 was not required, but about a 1-hour stimulation with the cytokine was sufficient to trigger the cells to synthesize PGI2 for several hours. Epoprostenol 149-153 interleukin 1 alpha Homo sapiens 27-31 2105090-5 1990 The recovery of PGI2 synthesis after aspirin was faster in IL-1-treated EC than in control cells. Epoprostenol 16-20 interleukin 1 alpha Homo sapiens 59-63 2105090-6 1990 These data define some of the characteristics of IL-1 stimulation of PGI2 and suggest that this process is mediated both by endogenous AA mobilization and by an increase in cyclooxygenase activity. Epoprostenol 69-73 interleukin 1 alpha Homo sapiens 49-53 2701650-4 1989 Recombinant human IL-1 was perfused through rabbit colons and we observed elevated levels of PGE2, TxB2 and 6-keto-PGF1 alpha, the stable metabolite of PGI2. Epoprostenol 152-156 interleukin 1 alpha Homo sapiens 18-22 2647121-1 1989 Incubation of human recombinant IL-1 alpha (hrIL-1 alpha) with cultured human endothelial cells induced a dose- and time-dependent increase in the release of prostacyclin (PGI2). Epoprostenol 158-170 interleukin 1 alpha Homo sapiens 32-42 2647121-1 1989 Incubation of human recombinant IL-1 alpha (hrIL-1 alpha) with cultured human endothelial cells induced a dose- and time-dependent increase in the release of prostacyclin (PGI2). Epoprostenol 172-176 interleukin 1 alpha Homo sapiens 32-42 2409598-0 1985 Prostacyclin synthesis induced in vascular cells by interleukin-1. Epoprostenol 0-12 interleukin 1 alpha Homo sapiens 52-65 2409598-3 1985 Interleukin-1-induced prostacyclin synthesis represents a new aspect of the interaction between the immune system (as well as other tissues) and the vessel wall and may serve as a basis for the development of new strategies in antithrombotic therapy. Epoprostenol 22-34 interleukin 1 alpha Homo sapiens 0-13 30867043-7 2019 Treatment with IL-1beta induced release of the prostacyclin metabolite 6-keto PGF1alpha in tendon cells isolated from diseased supraspinatus and Achilles tendons but not in cells from healthy comparator tendons. Epoprostenol 47-59 interleukin 1 alpha Homo sapiens 15-23 2959038-1 1987 The antirejection eicosanoids--PGE2, (PGD2), and PGI2--have an attenuating effect on T-cell proliferation by inhibition of IL-1, IL-2, and class II antigen expression on macrophages, and the prorejection eicosanoids--TXA2, LTB4, LTC4, and LTD4--enhance T-cell proliferation. Epoprostenol 49-53 interleukin 1 alpha Homo sapiens 123-127 3502509-3 1987 IL-1 induces synthesis of prostacyclin, platelet activating factor, thromboplastin and plasminogen activator inhibitor. Epoprostenol 26-38 interleukin 1 alpha Homo sapiens 0-4 3021848-4 1986 When stimulated monocytes were cultured with exogenous prostaglandins, including PGE2 and PGI2, expression of IL 1 was reversibly inhibited. Epoprostenol 90-94 interleukin 1 alpha Homo sapiens 110-114